Building the leading extracellular protein degradation company
11 - 50
π° $70M Series B on 2021-09
July 19
Lead global regulatory strategy for innovative therapeutics degrading extracellular and membrane-bound proteins.
πΊπΈ United States β Remote
β° Full Time
π΄ Lead
π Compliance